BIIB Q2 2019 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

Q2 2019 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$3.6B+7.8% YoY

Gross Profit

$3.1B86.8% margin

Operating Income

$2.0B54.1% margin

Net Income

$1.5B41.3% margin

EPS (Diluted)

$7.85

QoQ Revenue Growth

+3.6%

Cash Flow

Operating Cash Flow

$2.0B

Free Cash Flow

$1.8B

Stock-Based Comp.

$52M

Balance Sheet

Total Assets

$26.3B

Total Liabilities

$13.3B

Stockholders' Equity

$13.0B

Cash & Equivalents

$1.7B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.6B	$3.4B	+7.8%
Gross Profit	$3.1B	$2.9B	+7.0%
Operating Income	$2.0B	$1.2B	+61.2%
Net Income	$1.5B	$867M	+72.4%

Revenue Segments

MS Product Revenues

$2.2B59%

Interferon

$554M15%

SPINRAZA

$488M13%

TYSABRI product

$475M13%

Geographic Segments

UNITED STATES

$1.7B61%

Non-US

$1.1B39%